Objective: An MRI protocol for germinoma surveillance after complete remission has not been established. Moreover, the standard treatment for recurrent or refractory germinoma has not been determined. In this study, the authors explored the imaging characteristics of recurrent germinoma and discuss their institution's experience with multidisciplinary treatment of this malignancy.
Methods: The medical records of 16 patients (14 male, 2 female) with recurrent germinoma and 62 patients (52 male, 10 female) without recurrence who were treated at the authors' institution between 1989 and 2023 were retrospectively examined. Data including diagnostic imaging, tumor markers, treatment at diagnosis and recurrence, and overall survival were collected from patients' medical records and statistically analyzed.
Results: No patients with recurrence received craniospinal irradiation (CSI) as an initial therapy, and local irradiation was a significant risk factor of recurrence (p = 0.0072). The period between the start of first-line treatment and confirmation of the first recurrence ranged from 4.2 to 272 months (median 66.8 months). Among the recurrences, 13 tumors occurred outside the radiation field, including 6 cases of spinal cord/canal recurrence. One-third of patients did not exhibit elevated tumor marker levels in the serum. Fourteen patients had contrast-enhanced recurrent lesions. In the 2 patients with non-contrast-enhanced lesions, recurrence was detected by high signal intensity on diffusion-weighted imaging (DWI) and elevated tumor marker levels in CSF. Fifteen patients received chemotherapy for the first recurrence, and 14 received radiation therapy, with 9 receiving CSI. The patients who received CSI survived without further recurrence during the study period. However, the median progression-free survival and overall survival after the first recurrence among patients who did not undergo CSI were 12.2 and 37.4 months, respectively, which were shorter than those for patients treated with CSI (both p < 0.01, log-rank test).
Conclusions: Spinal MRI for surveillance in patients with recurrent germinoma, especially for those who do not receive CSI, is recommended. DWI might be useful for detecting recurrent germinoma. Aggressive treatment at the time of recurrence is crucial, and even if remission is achieved with chemotherapy, CSI for consolidation is important to prevent further recurrence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3171/2024.8.JNS241097 | DOI Listing |
J Neurosurg
January 2025
1Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima; and.
Objective: An MRI protocol for germinoma surveillance after complete remission has not been established. Moreover, the standard treatment for recurrent or refractory germinoma has not been determined. In this study, the authors explored the imaging characteristics of recurrent germinoma and discuss their institution's experience with multidisciplinary treatment of this malignancy.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Neurosurgery, Fu Jen Catholic University Hospital, New Taipei City, Taiwan
A woman in her early 20s presented with progressive low back pain, leg weakness and sphincter dysfunction. MRI revealed a 5 × 1.5 cm intramedullary tumour at the T12-L2 level.
View Article and Find Full Text PDFBMC Cancer
January 2025
National Center for Neurological Disorders, Shanghai, 200052, China.
Background: To determine the optimal treatment modality for intracranial germinoma (IG).
Materials And Methods: A search of Medline, Embase, Web of Science and Cochrane Library was conducted up to April, 2024. Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated.
Rev Med Suisse
November 2024
Service d'urologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
BJU Int
February 2025
EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!